Tetra Bio-Pharma has announced results from the artificial intelligence (AI) study of ARDS-003, along with Favipiravir, against acute respiratory distress syndrome (ARDS), Sepsis, and Covid-19 through the PREPAiRE platform.

The AI-powered PREPAiRE platform has been designed to purposely integrate target identification, validation, optimisation of lead discovery, drug synthesis, and preclinical testing.

In the clinical trial, it was found that Tetra’s investigational therapeutic, ARDS-003, acts against various ARDS and Sepsis targets such as IL-6 and IL-8.

ARDS-003 contains the active pharmaceutical ingredient Onternabez, which plays a key role in mitigating the inflammatory response in various inflammatory condition targets.

Favipiravir is capable of controlling the source of infection while Onternabez would contribute to the antiviral efficacy and control the result of the infection.

Cellvera, directly or through its affiliates, holds exclusive global rights to Favipiravir under the brand names Avigan 200mg and Qifenda 400mg/800mg, and the injectable formulation.

Tetra Bio-Pharma CEO and chief regulatory officer Dr Guy Chamberland said: “We are very pleased by these artificial intelligence results, as well as the recent positive results from the PIONEER trial.

“This underscores our commitment with Cellvera to developing an innovative combination drug candidate to combat viral diseases. We are more excited than ever about our collaboration with Cellvera and the possibility of delivering the next scientific breakthroughs.”

PIONEER is a global, randomised controlled trial of early intervention in hospitalised Covid-19 patients.

Sponsored by Chelsea and Westminister Hospital NHS Foundation Trust, the trial recruited 499 patients from Brazil, UK, and Mexico.

Patients who were admitted to hospitals with proven or suspected Covid-19 during May 2020 to May 2021 were part of this trial.

The study was supported by NEAT ID and financially supported by a group of organisations and individuals.

Researchers reported that treatment with Favipiravir given orally benefited recovery and mechanical ventilation-free survival among patients younger than 60 years.

Time to a two-point improvement in the WHO ordinal scale or discharge, whichever occurred first, was the primary outcome.

Secondary outcomes focused on health care resource utilisation and mortality.